<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Zolgensma (Onasemnogene Abeparvovec)</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>Zolgensma (Gene Therapy)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>[smn1](/proteins/smn1-protein) gene replacement</td>
</tr>
<tr>
<td class="label">Route</td>
<td>IV (one-time) or IT (one-time)</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Single dose</td>
</tr>
<tr>
<td class="label">[blood-brain-barrier](/entities/blood-brain-barrier) crossing</td>
<td>Yes (IV route)</td>
</tr>
<tr>
<td class="label">Age range</td>
<td><2 yr (IV); 2–<18 yr (IT)</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Gene replacement</td>
</tr>
</table>
Zolgensma (Onasemnogene Abeparvovec) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Zolgensma (Onasemnogene Abeparvovec)</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>Zolgensma (Gene Therapy)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>[smn1](/proteins/smn1-protein) gene replacement</td>
</tr>
<tr>
<td class="label">Route</td>
<td>IV (one-time) or IT (one-time)</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Single dose</td>
</tr>
<tr>
<td class="label">[blood-brain-barrier](/entities/blood-brain-barrier) crossing</td>
<td>Yes (IV route)</td>
</tr>
<tr>
<td class="label">Age range</td>
<td><2 yr (IV); 2–<18 yr (IT)</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Gene replacement</td>
</tr>
</table>
Zolgensma (Onasemnogene Abeparvovec) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Zolgensma (generic name onasemnogene abeparvovec-xioi; development code AVXS-101) is a recombinant adeno-associated virus serotype 9 (AAV9)-based gene therapy developed by AveXis (now part of [Novartis](/companies/novartis) Gene Therapies) for the treatment of [spinal-muscular-atrophy](/diseases/spinal-muscular-atrophy) (SMA). It delivers a functional copy of the human [smn1](/proteins/smn1-protein) gene to motor neuron cells, addressing the root genetic cause of SMA — loss-of-function mutations in the SMN1 gene that lead to insufficient levels of survival motor neuron ([smn](/proteins/smn) protein and progressive [motor-neurons](/cell-types/motor-neurons) degeneration.[@mendell2017] [@novartis2025]
The U.S. Food and Drug Administration (FDA) originally approved Zolgensma in May 2019 for pediatric patients under 2 years of age with SMA, making it one of the first [gene-therapy](/therapeutics/gene-therapy) approved for a [neurodegenerative disease. In December 2025, the FDA expanded approval to include patients aged 2 to under 18 years via intrathecal administration, based on the pivotal STEER trial results.[@novartis2025] Zolgensma was initially priced at approximately $2.125 million for a single dose, making it one of the most expensive pharmaceutical products in history at launch. [@lefebvre1995]
[spinal-muscular-atrophy](/diseases/spinal-muscular-atrophy) is caused by homozygous deletions or mutations in the [smn1](/proteins/smn1-protein) gene on chromosome 5q13, resulting in deficient production of the full-length SMN protein essential for [motor-neurons](/cell-types/motor-neurons) survival and function. The severity of SMA is modulated by the copy number of a closely related gene, SMN2, which produces predominantly a truncated, unstable SMN protein due to alternative splicing of exon 7.[@lefebvre1995] [@foust2010]
Onasemnogene abeparvovec uses a non-replicating, self-complementary AAV9 vector to deliver a functional copy of the human SMN1 transgene under the control of a cytomegalovirus (CMV) enhancer/chicken β-actin hybrid promoter. Key features of the mechanism include: [@pellizzoni1998]
Once the AAV9 capsid enters the motor neuron via receptor-mediated endocytosis (primarily through AAVR, the AAV receptor), it trafficks through the endosomal pathway to the nucleus. The self-complementary DNA genome is released and forms stable episomal concatemers. Transcription from the hybrid CMV/CBA promoter produces full-length SMN mRNA, which is translated into functional SMN protein. This protein restores the assembly of small nuclear ribonucleoproteins (snRNPs), which are essential for pre-mRNA splicing in motor [neurons](/entities/neurons).[@pellizzoni1998] [@mda2026]
The first-in-human START trial (NCT02122952) enrolled 15 infants with SMA type 1 who received intravenous onasemnogene abeparvovec. The high-dose cohort (n=12) showed remarkable results: all 12 patients were alive and free of permanent ventilation at 20 months of age (compared to the 8% expected natural history), with 11 of 12 achieving head control and 9 of 12 able to sit independently. Two patients could walk independently — milestones never achieved in untreated SMA type 1.[@mendell2017] [@day2021]
Long-term follow-up through 7+ years has demonstrated durable SMN protein expression and sustained motor function, with no evidence of transgene expression decline, confirming the one-time treatment paradigm.[@mda2026] [@muntoni2025]
The pivotal STR1VE-US (NCT03306277) and STR1VE-EU (NCT03461289) trials enrolled symptomatic SMA type 1 infants. In STR1VE-US: [@feldman2023]
The STEER trial (NCT05089656) was a randomized, sham-controlled study evaluating intrathecal onasemnogene abeparvovec in 126 treatment-naïve patients aged 2 to <18 years with SMA type 2. At 52 weeks: [@malone2022]
The STRENGTH trial (NCT05386680) evaluated intrathecal onasemnogene abeparvovec in patients aged 2 to <18 years who had previously been treated with [nusinersen](/therapeutics/nusinersen) (Spinraza) or [risdiplam](/therapeutics/risdiplam) (Evrysdi). Results demonstrated a favorable safety profile consistent with treatment-naïve populations and suggested clinical benefit in patients switching from other SMA therapies.[@muntoni2025] [@fda2019]
The most significant safety concern is hepatotoxicity, reported in approximately 34–43% of patients across clinical trials. The mechanism is believed to involve immune-mediated liver injury triggered by AAV9 capsid transduction of hepatocytes and subsequent T-cell recognition of viral capsid epitopes:
Thrombotic microangiopathy has been identified as a rare but serious adverse event in the postmarketing setting:
Zolgensma's initial list price of $2.125 million made it a landmark case in pharmaceutical pricing debates. Economic analyses have argued that the one-time cost may be offset by avoided lifetime treatment costs of chronic therapies (nusinersen costs approximately $750,000 in the first year and $375,000 annually thereafter) and by the substantial reduction in healthcare utilization for SMA patients.[@malone2022]
Novartis has implemented outcomes-based agreements with payers and a managed access program to improve global availability, particularly in countries where SMA newborn screening enables early detection and treatment.
The study of Zolgensma (Onasemnogene Abeparvovec) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate